Login to Your Account



Ardelyx, AstraZeneca Sign $272M NHE3 Inhibitor Deal

By Staff Reports


Tuesday, October 9, 2012
Ardelyx Inc.'s goal of landing a partnership in 2012 panned out Monday, with the Fremont, Calif.-based company inking a potential $272.5 million deal with AstraZeneca for rights to its NHE3 inhibitor program, including Phase II-ready compound RDX5791.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription